Non-animal Alternative Testing Market Size Report – 2032

Non-animal Alternative Testing Market – By Product, By Method, By Technology, By Application, By End Use, & Global Forecast, 2024 – 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market scope &amp; definition

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3.1&nbsp;&nbsp;&nbsp; Base year calculation

1.3.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.4&nbsp;&nbsp;&nbsp; Forecast model

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.5.2&nbsp;&nbsp;&nbsp; Data mining sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary 

2.1&nbsp;&nbsp;&nbsp; Industry 3600 synopsis

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights 

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Technological advances in drug development

3.2.1.2&nbsp;&nbsp;&nbsp; Growing investments and research grants for developing alternative technologies

3.2.1.3&nbsp;&nbsp;&nbsp; Increasing ban on using animal models for research purposes

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp; Stringent regulations related to safety, efficacy and quality

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Regulatory landscape

3.4.1&nbsp;&nbsp;&nbsp; U.S.

3.4.2&nbsp;&nbsp;&nbsp; Europe

3.5&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.6&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2023

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis

4.3&nbsp;&nbsp;&nbsp; Competitive analysis of major market players cell line

4.4&nbsp;&nbsp;&nbsp; Competitive analysis of major market players tissue line

4.5&nbsp;&nbsp;&nbsp; Competitive analysis of major market players organ-on-chips

4.6&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.7&nbsp;&nbsp;&nbsp; Strategy dashboard

4.8&nbsp;&nbsp;&nbsp; Strategy outlook matrix

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Product Type, 2021 &ndash; 2032 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Organ-on-chips

5.3&nbsp;&nbsp;&nbsp; Cell lines

5.4&nbsp;&nbsp;&nbsp; Tissue lines

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Method, 2021 &ndash; 2032 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Ex vivo testing

6.3&nbsp;&nbsp;&nbsp; Computer modelling

6.4&nbsp;&nbsp;&nbsp; Cellular assay

6.5&nbsp;&nbsp;&nbsp; Biochemical assay

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Technology, 2021 &ndash; 2032 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Cell culture technology

7.3&nbsp;&nbsp;&nbsp; High throughput technology

7.4&nbsp;&nbsp;&nbsp; Molecular imaging technology

7.5&nbsp;&nbsp;&nbsp; Omics technology

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Application, 2021 &ndash; 2032 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; Infectious diseases

8.3&nbsp;&nbsp;&nbsp; Immunological diseases

8.4&nbsp;&nbsp;&nbsp; Oncology

8.5&nbsp;&nbsp;&nbsp; Cardiovascular diseases

8.6&nbsp;&nbsp;&nbsp; Diabetes

8.7&nbsp;&nbsp;&nbsp; Genetic diseases

8.8&nbsp;&nbsp;&nbsp; Neurological diseases

Chapter 9&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By End Use, 2021 &ndash; 2032 ($ Mn)

9.1&nbsp;&nbsp;&nbsp; Key trends

9.2&nbsp;&nbsp;&nbsp; Pharmaceutical companies

9.3&nbsp;&nbsp;&nbsp; Biotechnological companies

9.4&nbsp;&nbsp;&nbsp; Research institutes and academics

9.5&nbsp;&nbsp;&nbsp; CROs

9.6&nbsp;&nbsp;&nbsp; Other End Use

Chapter 10&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2021 &ndash; 2032 ($ Mn)

10.1&nbsp;&nbsp;&nbsp; Key trends

10.2&nbsp;&nbsp;&nbsp; North America

10.2.1&nbsp;&nbsp;&nbsp;U.S.

10.2.2&nbsp;&nbsp;&nbsp;Canada

10.3&nbsp;&nbsp;&nbsp; Europe

10.3.1&nbsp;&nbsp;&nbsp;Germany

10.3.2&nbsp;&nbsp;&nbsp;UK

10.3.3&nbsp;&nbsp;&nbsp;France

10.3.4&nbsp;&nbsp;&nbsp;Italy

10.3.5&nbsp;&nbsp;&nbsp;Spain

10.4&nbsp;&nbsp;&nbsp; Asia Pacific

10.4.1&nbsp;&nbsp;&nbsp;China

10.4.2&nbsp;&nbsp;&nbsp;Japan

10.4.3&nbsp;&nbsp;&nbsp;India

10.4.4&nbsp;&nbsp;&nbsp;Australia

10.4.5&nbsp;&nbsp;&nbsp;South Korea

10.5&nbsp;&nbsp;&nbsp; Latin America

10.5.1&nbsp;&nbsp;&nbsp;Brazil

10.5.2&nbsp;&nbsp;&nbsp;Mexico

10.6&nbsp;&nbsp;&nbsp; Middle East and Africa

10.6.1&nbsp;&nbsp;&nbsp;South Africa

10.6.2&nbsp;&nbsp;&nbsp;Saudi Arabia

Chapter 11&nbsp;&nbsp;&nbsp;Company Profiles 

11.1&nbsp;&nbsp;&nbsp; AlveoliX

11.2&nbsp;&nbsp;&nbsp; BICO GROUP

11.3&nbsp;&nbsp;&nbsp; CN Bio Innovations

11.4&nbsp;&nbsp;&nbsp; Emulate

11.5&nbsp;&nbsp;&nbsp; Hesperos

11.6&nbsp;&nbsp;&nbsp; InSphero

11.7&nbsp;&nbsp;&nbsp; Lonza Group

11.8&nbsp;&nbsp;&nbsp; Merck

11.9&nbsp;&nbsp;&nbsp; MIMETAS

11.10&nbsp;&nbsp;&nbsp; Thermo Fisher Scientific

11.11&nbsp;&nbsp;&nbsp; TissUse

11.12&nbsp;&nbsp;&nbsp; VITROCELL Systems

&nbsp;&nbsp;&nbsp;

Non-animal Alternative Testing Market

Customize This Report